Adastra Labs Receives Health Canada Approval to Handle Cocaine


Adastra Labs Receives Health Canada Approval to Handle Cocaine

Adastra Labs granted approval to include cocaine in controlled substances dealer's license

Expert Analysis: Top 5 Canadian Stocks to Watch and Buy Now
Strathmore Plus Uranium Corp Plans 100-Hole Drill Program
Canadian inflation eases in January, but mortgage and food costs remain high

Adastra Labs Inc., a subsidiary of Adastra Holdings Ltd., has received approval from Health Canada to amend its controlled substances dealer’s license to include cocaine. This license allows Adastra to legally possess, produce, sell, and distribute the drug. The approval was granted on February 17, 2023, making Adastra one of the few licensed entities in Canada to handle the controlled substance.

Top Reads: Carlyle Commodities Corp Completes Phase 1 Drill Program at Newton Gold-Silver Project

The license amendment also permits Adastra to interact with up to 250 grams of cocaine, as well as import coca leaves to manufacture and synthesize the substance. The company’s CEO, Michael Forbes, stated that they will evaluate the commercialization of this substance to position themselves to support the demand for a safe supply of cocaine.

Adastra Labs granted approval to include cocaine in controlled substances dealer’s license

Mr. Forbes is no stranger to addiction medicine as he has extensive experience working as a pharmacist in multiple methadone pharmacies. He also has a specialty in compounding pharmacy and formulation and founded Ageless Living longevity-based interdisciplinary clinics. Mr. Forbes piloted a needle exchange program in 2010 at the direction of the Centres for Disease Control and Prevention.

In addition to the cocaine amendment, Adastra’s controlled drug and substances dealer license also permits the company to possess, produce, sell, and distribute up to 1,000 grams of psilocybin and psilocin. This license was granted on August 24, 2022.

Adastra’s Operations

Adastra is a leading manufacturer and supplier of ethnobotanical and cannabis science products, catering to adult-use medical markets and therapeutic applications. The company operates a 13,500-square-foot, Health Canada licensed facility located in Langley, B.C. for extraction, distillation, and manufacturing of cannabis-derived products. Adastra is recognized as a high-capacity processor and co-manufacturer throughout Canada, with its Phyto Extractions brand available on shelves at over 1,400 adult-use retailers across the country. The company has also taken steps to become a licensed cultivator, tester, extractor, and seller of controlled substances, including psilocybin and psilocin, under its controlled substances dealer license. Adastra operates PerceiveMD, a multidisciplinary manufacturer for medical cannabis and psychedelic therapies, working alongside practitioners and healthcare professionals within the regulated environment to create efficacious remedies that address the actual needs of patients.

With a three-year exemption under the Controlled Drugs and Substances Act (CDSA) in British Columbia for adults 18 years and older to possess up to 2.5 grams of opioids, cocaine, methamphetamine, MDMA or some combination thereof, between Jan. 31, 2023, and Jan. 31, 2026, Adastra is poised to position itself at the forefront of drug regulations.